Page 91 - CIBEREHD2016-ENG

Most relevant scientific articles
• Bozic M., Guzman C., Benet M., Sanchez-Campos S., Garcia-Monzon C., Gari E. et al. Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis. Journal of Hepatology. 2016.
• Prieto-Dominguez N., Ordonez R., Fernandez A., Mendez-Blanco C., Baulies A., Garcia-Ruiz C. et al. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. Journal of Pineal Research. 2016.
• Crespo I., San-Miguel B., Sanchez D.I., Gonzalez-Fernandez B., Alvarez M., Gonzalez-Gallego J. et al. Melatonin inhibits the sphingosine kinase 1/sphingosine-1-phosphate signaling pathway in rabbits with fulminant hepatitis of viral origin. Journal of Pineal Research. 2016.
• Booth L., Roberts J.L., Ecroyd H., Tritsch S.R., Bavari S., Reid S.P. et al. AR-12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication. Journal of Cellular Physiology. 2016;231(10):2286-2302.
• Prieto-Dominguez N., Ordonez R., Fernandez A., Garcia-Palomo A., Muntane J., Gonzalez-Gallego J. et al. Modulation of autophagy by sorafenib: Effects on treatment response. Frontiers in Pharmacology. 2016;7(JUN).
Hightlights
The research group has published seven articles in indexed journals (three in collaboration with other CIBEREHD groups); five are 1st quartile (including three 1st decile). Among competitive research projects developed, it is worth mentioning those related with the effect of intestinal microbiota modulation
by flavonoid treatment, microbiota transplant and exercise in experimental models of non-alcoholic fatty liver disease (financed by the Plan Estatal de Investigación Científica y Técnica and the Junta
de Castilla y León), or the therapeutic role of melatonin in experimental models of liver fibrosis and hepatocarcinoma. Moreover, studies have been carried out on the role of vitamin D receptor in the appearance and progression of hepatic steatosis or the antiviral efficacy of new chaperone inhibitors. Concerning translation of results to clinical practice we have participated in one clinical assay on the efficacy and safety of ABT-493/ABT-530 in adults with chronic infection by HCV GT1 and cooperate with the European Prospective Drug-Induced Liver Injury Registry (Pro-Euro-DILI Registry). During this period we have collaborated with the following CIBEREHD groups: Program 1 (J. V. Castell, J. C. Fernández-Checa, R. Andrade, M. de la Mata, C. García-Monzón), Program 3 (M. Romero, J. García-Samaniego), Program 4 (F. J. Padillo, P. Parrilla). We have also maintained international collaborations with the Universities of Arizona, Virginia Commonwealth and Georgia Regents (USA), the Army Medical Research Institute of Infectious Diseases (USA), the University de Wollongong (Australia), the University of Buenos Aires (Argentina), the Universidad Autónoma of Chile and the Federal Universities of Santa María and Rio Grande do Sul (Brazil).
EHD
research Groups 91